SCHEDULE: Samsara Funds Boost Alumis Stake to 5.4%
Beneficial Ownership Update
Samsara BioCapital and Opportunity Fund increased their beneficial ownership in Alumis Inc. to 5.4% through recent open market purchases and participation in a public offering.
Summary
- Samsara Opportunity Fund acquired additional shares of Alumis Inc. common stock between November 26, 2025, and January 9, 2026.
- Purchases included open market transactions at prices ranging from $7.31 to $11.005 per share.
- A significant purchase of 588,235 shares was made on January 9, 2026, at $17.00 per share from underwriters of Alumis's public offering.
- The total aggregate purchase price for these acquisitions was $15,209,937.96.
- Srinivas Akkaraju, through his control of Samsara BioCapital GP, LLC and Samsara Opportunity Fund GP, LLC, beneficially owns 6,345,219 shares, representing 5.4% of Alumis Inc.'s common stock.
- The percentage ownership is calculated based on 117,505,995 shares outstanding, including 20,297,500 shares issued in the January 2026 Offering.
Sentiment
Score: 8
Explanation: The significant increase in beneficial ownership by a specialized life sciences fund, including participation in a public offering at a higher price, reflects strong investor confidence and a positive outlook on Alumis Inc.'s future. This indicates a bullish stance from a sophisticated investor.
Positives
- Increased beneficial ownership by institutional investors like Samsara BioCapital and Samsara Opportunity Fund signals confidence in Alumis Inc.'s future prospects.
- Significant investment of over $15.2 million by Samsara Opportunity Fund demonstrates a strong commitment to the company.
- Participation in the January 2026 Offering at $17.00 per share, a higher price than previous open market purchases, suggests a positive view on the company's valuation post-offering.
Future Outlook
NA
Industry Context
This filing indicates continued institutional interest and investment in the biotechnology or pharmaceutical sector, represented by Alumis Inc. The participation in a public offering and subsequent open market purchases by a specialized life sciences fund like Samsara BioCapital suggest a positive long-term view on Alumis's potential within its specific therapeutic area, aligning with broader trends of capital allocation towards promising biotech ventures.
Stakeholder Impact
- Shareholders: Increased institutional ownership could be viewed positively, potentially signaling validation of the company's strategy and future prospects, which may lead to increased investor confidence and potentially share price appreciation.
- Company Management: The substantial investment by a prominent life sciences fund could provide a vote of confidence and potentially open doors for strategic advice or support.
Key Dates
| Date | Description |
|---|---|
| 2025-11-06 | Date as of which 97,208,495 shares of voting common stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q. |
| 2025-11-13 | Date of filing of Issuer's Quarterly Report on Form 10-Q. |
| 2025-11-24 | Date of original Schedule 13D filing by the Reporting Persons. |
| 2025-11-26 | Samsara Opportunity Fund purchased 48,537 shares of common stock. |
| 2025-11-28 | Samsara Opportunity Fund purchased 38,702 shares of common stock. |
| 2025-12-01 | Samsara Opportunity Fund purchased 86,350 shares of common stock. |
| 2025-12-02 | Samsara Opportunity Fund purchased 96,000 shares of common stock. |
| 2025-12-03 | Samsara Opportunity Fund purchased 100,000 shares of common stock. |
| 2025-12-04 | Samsara Opportunity Fund purchased 66,027 shares of common stock. |
| 2025-12-05 | Samsara Opportunity Fund purchased 186,377 shares of common stock in three tranches. |
| 2026-01-09 | Date of event requiring filing of this statement; Samsara Opportunity Fund purchased 588,235 shares of common stock from underwriters of the Issuer's public offering; Date of filing of Issuer's Current Report on Form 8-K reporting 20,297,500 shares issued in the January 2026 Offering. |
| 2026-01-13 | Date of signing of this Amendment No. 1 to Schedule 13D. |
Recommendation
strong buyThe substantial increase in beneficial ownership by Samsara BioCapital and Samsara Opportunity Fund, particularly their participation in a public offering at a premium price of $17.00 per share, signals strong conviction from a sophisticated institutional investor. This aggressive accumulation of shares, totaling over $15.2 million, suggests a belief that Alumis Inc. is significantly undervalued or poised for substantial growth. Such a move by a specialized life sciences fund often precedes positive developments or reflects deep due diligence indicating strong future prospects. This action provides a compelling signal for other investors to consider a 'strong buy' position.
Keywords
Alumis Inc., ALUS, Samsara BioCapital, Samsara Opportunity Fund, Schedule 13D/A, beneficial ownership, common stock, public offering, institutional investment, Srinivas Akkaraju
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.